Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumor activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.

Abstract: Isolated antibodies or antigen binding portions thereof that bind to CD1d. These antibodies and antigen binding portions thereof have application in treatment of conditions involving NKT cell effector function.

Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.

Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.

Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models.

Abstract: The present invention provides humanized antibodies and binding domains thereof with anti-tumor activity. In particular the humanized antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.

Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.

Abstract: The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.

Abstract: The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.

Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models.

Abstract: Particular aspects provide novel methods for analysis of ion populations, the methods comprising filtering and selecting an ion population using a low-field dual-gate ion mobility spectrometer comprising a drift tube, the spectrometer operating at a pressure of at least 100 Torr, to provide mobility-selected ions. Certain aspects comprise: (i) subsequently accumulating the low-field selected ions in an ion trap (e.g., an MS ion trap) and mass spectrometry analysis; (ii) introducing the low-field selected ions into a high-field ion mobility spectrometer for separating thereby (optionally followed by mass spectrometry); and (iii) introducing the low-field selected ions into an ion trap mass spectrometer, and subsequently into a second low-field ion mobility spectrometer (e.g., a non-dual gate spectrometer operating at less than about 100 Torr). Additional aspects provide novel apparatus and combination thereof for performing the disclosed methods.

Abstract: The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced.

Abstract: Particular aspects provide novel methods for analysis of ion populations, the methods comprising filtering and selecting an ion population using a low-field dual-gate ion mobility spectrometer comprising a drift tube, the spectrometer operating at a pressure of at least 100 Torr, to provide mobility-selected ions. Certain aspects comprise: (i) subsequently accumulating the low-field selected ions in an ion trap (e.g., an MS ion trap) and mass spectrometry analysis; (ii) introducing the low-field selected ions into a high-field ion mobility spectrometer for separating thereby (optionally followed by mass spectrometry); and (iii) introducing the low-field selected ions into an ion trap mass spectrometer, and subsequently into a second low-field ion mobility spectrometer (e.g., a non-dual gate spectrometer operating at less than about 100 Torr). Additional aspects provide novel apparatus and combination thereof for performing the disclosed methods.